Compare LARK & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LARK | KROS |
|---|---|---|
| Founded | 1885 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.5M | 206.0M |
| IPO Year | 2001 | 2020 |
| Metric | LARK | KROS |
|---|---|---|
| Price | $30.85 | $10.61 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $21.86 |
| AVG Volume (30 Days) | 16.8K | ★ 313.0K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | 35.84 | ★ 146.00 |
| EPS | ★ 0.83 | N/A |
| Revenue | N/A | ★ $243,864,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,751.79 |
| P/E Ratio | $37.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.57 | $9.69 |
| 52 Week High | $32.39 | $22.55 |
| Indicator | LARK | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 55.39 | 45.71 |
| Support Level | $25.46 | $10.14 |
| Resistance Level | $30.80 | $11.55 |
| Average True Range (ATR) | 0.63 | 0.58 |
| MACD | -0.07 | -0.08 |
| Stochastic Oscillator | 41.45 | 13.77 |
Landmark Bancorp Inc is the bank holding company for Landmark National Bank, which is dedicated to providing quality financial and banking services. The Bank has continued to focus on increasing its originations of commercial, commercial real estate (CRE), and agricultural loans, which management believes will be more profitable and provide more growth for the Bank than traditional one-to-four-family residential real estate lending. In addition, it also invests in certain investment and mortgage-related securities using deposits and other borrowings as funding sources. Its primary deposit gathering and lending markets are geographically diversified with locations in central, eastern, southeast, and Southwest Kansas.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.